Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma
An. bras. dermatol
;
91(3): 368-371, graf
Article
Dans Anglais
| LILACS
| ID: lil-787311
ABSTRACT
Abstract Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Tumeurs cutanées
/
Méthotrexate
/
Lymphome T cutané
/
Étanercept
/
Immunosuppresseurs
Type d'étude:
Etude diagnostique
Limites du sujet:
Humains
/
Mâle
langue:
Anglais
Texte intégral:
An. bras. dermatol
Thème du journal:
Dermatologie
Année:
2016
Type:
Article
Pays d'affiliation:
Chine
Institution/Pays d'affiliation:
Sun Yat-sen University/CN
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS